Insulin receptor substrate 1 is a substrate of the Pim protein kinases

Jin H. Song, Sathish K R Padi, Libia A. Luevano, Mark D. Minden, Daniel J. DeAngelo, Gary Hardiman, Lauren E. Ball, Noel A. Warfel, Andrew Kraft

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates. Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)20152-20165
Number of pages14
JournalOncotarget
Volume7
Issue number15
DOIs
StatePublished - Apr 12 2016

Fingerprint

Insulin Receptor Substrate Proteins
Protein Kinases
Phosphorylation
Clinical Trials, Phase I
Phase II Clinical Trials
Protein-Serine-Threonine Kinases
Mitochondrial Proteins
Oxidative Phosphorylation
Hematologic Neoplasms
Enzymes
Drug Delivery Systems
Computational Biology
Heterografts
Half-Life
Neoplasms
Proteins
Biomarkers
Pharmacology
Insulin
Glucose

Keywords

  • IGF1
  • Insulin
  • IRS1
  • Pim kinase
  • Pim kinase inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Song, J. H., Padi, S. K. R., Luevano, L. A., Minden, M. D., DeAngelo, D. J., Hardiman, G., ... Kraft, A. (2016). Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget, 7(15), 20152-20165. https://doi.org/10.18632/oncotarget.7918

Insulin receptor substrate 1 is a substrate of the Pim protein kinases. / Song, Jin H.; Padi, Sathish K R; Luevano, Libia A.; Minden, Mark D.; DeAngelo, Daniel J.; Hardiman, Gary; Ball, Lauren E.; Warfel, Noel A.; Kraft, Andrew.

In: Oncotarget, Vol. 7, No. 15, 12.04.2016, p. 20152-20165.

Research output: Contribution to journalArticle

Song, JH, Padi, SKR, Luevano, LA, Minden, MD, DeAngelo, DJ, Hardiman, G, Ball, LE, Warfel, NA & Kraft, A 2016, 'Insulin receptor substrate 1 is a substrate of the Pim protein kinases', Oncotarget, vol. 7, no. 15, pp. 20152-20165. https://doi.org/10.18632/oncotarget.7918
Song JH, Padi SKR, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G et al. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12;7(15):20152-20165. https://doi.org/10.18632/oncotarget.7918
Song, Jin H. ; Padi, Sathish K R ; Luevano, Libia A. ; Minden, Mark D. ; DeAngelo, Daniel J. ; Hardiman, Gary ; Ball, Lauren E. ; Warfel, Noel A. ; Kraft, Andrew. / Insulin receptor substrate 1 is a substrate of the Pim protein kinases. In: Oncotarget. 2016 ; Vol. 7, No. 15. pp. 20152-20165.
@article{59e911b68eb74114b0123ee751b758d6,
title = "Insulin receptor substrate 1 is a substrate of the Pim protein kinases",
abstract = "The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates. Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.",
keywords = "IGF1, Insulin, IRS1, Pim kinase, Pim kinase inhibitor",
author = "Song, {Jin H.} and Padi, {Sathish K R} and Luevano, {Libia A.} and Minden, {Mark D.} and DeAngelo, {Daniel J.} and Gary Hardiman and Ball, {Lauren E.} and Warfel, {Noel A.} and Andrew Kraft",
year = "2016",
month = "4",
day = "12",
doi = "10.18632/oncotarget.7918",
language = "English (US)",
volume = "7",
pages = "20152--20165",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "15",

}

TY - JOUR

T1 - Insulin receptor substrate 1 is a substrate of the Pim protein kinases

AU - Song, Jin H.

AU - Padi, Sathish K R

AU - Luevano, Libia A.

AU - Minden, Mark D.

AU - DeAngelo, Daniel J.

AU - Hardiman, Gary

AU - Ball, Lauren E.

AU - Warfel, Noel A.

AU - Kraft, Andrew

PY - 2016/4/12

Y1 - 2016/4/12

N2 - The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates. Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.

AB - The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates. Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.

KW - IGF1

KW - Insulin

KW - IRS1

KW - Pim kinase

KW - Pim kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84964733969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964733969&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7918

DO - 10.18632/oncotarget.7918

M3 - Article

C2 - 26956053

AN - SCOPUS:84964733969

VL - 7

SP - 20152

EP - 20165

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -